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BOCKERIA ET AL.: Efficacy of Statin Therapy in the Prevention of Atrial Fibrillation in Patients after Coronary
Artery Bypass Grafting: Statin medication has shown good results in the prevention of the postoperative atrial
fibrillation (AF) after coronary artery bypass grafting (CABG). Objective: To assess the role of statin medication in
the prevention of AF after CABG. Material and Methods: A retrospective analysis of 225 medical records of the
patients, aged 57.5±7.9 years (mean±SD), who underwent CABG. All patients was divided into two groups. The first
group included those patients who did not received statin medication (n=93). We named this group as nSt-patients.
Second group included patients who receive statin medication (n=132). We named this group as St-patients. Clinical
data on all included patients were obtained in pre-, intra- and postoperative periods. The risk of occurrence of
postoperative AF was evaluated using the Cox-regression model. Continuous variables were reported as medians
(Me) with inter-quartile ranges (Q1, Q3). Categorical data were presented as percentages. Results: The rate of AF was
29% in nSt-patients and 9% in St-patients (P<0.001). On Day 4 after surgery, white blood cells (WBC) count was
10.9 (9.0, 13.0) ×109 e/L in nSt-patients and 9.1 (7.6, 10.0) in St-patients (P<0.001). An analysis of WBC count dayto-day changes was performed in a subgroup of patients who developed postoperative AF. This analysis showed that
the peak WBC numbers occurred on the day of arrhythmia manifestation. In this subgroup, WBC count increased
from 10.4 (7.5, 12.3) on Day 1 after surgery to 10.9 (9.0, 13.0) ×109 e/L on the day of onset of AF (P=0.008).
According to the Cox-regression model, the risk of AF was 3.68 for prior AF and 0.31 for statin medication. Conclusion:
In our study, we showed an association between the use of statin medication and AF in early postoperative period.
(J HK Coll Cardiol 2016;24:1-10)
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Introduction
Atrial fibrillation (AF) is the most common
rhythm disorder occurring after coronary artery bypass
grafting (CABG). AF occurs in 25 to 30% of patients
after CABG.1-4 The onset of AF is associated with a high
risk of postoperative complications, such as
hemodynamic instability, stroke and myocardial
infarction. All these complications lead to prolonged
hospital stay and large economic cost.5-7
Some researchers recommend amiodarone and
beta-blockers to reduce the risk of postoperative AF.8-10
However, it should be noted that such preventive therapy
does not seem to be safe in all patients because of adverse
effects of these drugs, such as hypotension and
bradycardia associated with beta-blockers and
proarrhythmogenic effect of amiodarone. 11 The
difficulties in the prevention of AF after CABG is
explained by a poor understanding of both the
mechanisms of onset of AF in patients after the surgery
and the impact of intraoperative and postoperative
factors on the electrophysiological properties of the
atria.5,12
Any cardiac surgery is associated with an
inflammatory process that includes systemic and local
inflammation. 13,14 CABG is associated with the
increasing of the inflammatory markers, such as Creactive protein and interleukin-6, 13 with a peak
concentration on day 2 to 4 after the surgery, just when
the postoperative AF morbidity achieves its highest
rate.13,15 Inflammation is supposed to be a cause of the
AF by affecting as structural as electrophysiological
properties of the atria.16
In a number of previous studies, statin therapy
has been shown to be effective in prevention of the AF
after CABG. 16-19 The reduction in CABG-related
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inflammatory markers was noticed when statins were
used routinely prior and after the surgery.13,20,21 However,
other studies failed to demonstrate an antiarrhythmic
affect of statins after open-heart surgery.22-24
The objective of this study is to assess the role of
statin therapy in the prevention of the AF after GABG.

Material and Methods
General Design of Study
Design of this study was approved by the Ethics
Committee (Protocol no.9, 07 February 2014) of the
Bakoulev Center for Cardiovascular Surgery in Moscow,
Russia.
The data on the health status of all consecutive
patients with CABG were gathered retrospectively in
the Department of Surgical Treatment for Interactive
Pathology, Bakoulev Scientific Center for
Cardiovascular Surgery (Moscow, Russia). Informed
consent was obtained from all participants.
The following inclusion criterion was established
for the purposes of the study: isolated CABG performed
in 2013.
The patients were not included in our study if
they matched the following criteria:
i) Concomitant surgery (e.g. CABG with valve repair/
prosthesis, CABG with aneurysmectomy, CABG
with Maze-procedure, CABG with surgical
correction of ventricular septal defect)
ii) Severe renal failure (creatinine clearance
calculated by the Cockroft-Gault formula <50 mL/
min)
iii) Hypo- or hyperkalaemia
iv) Left ventricle ejection fraction (LVEF) <35%
v) Thyroid dysfunction (hyper- or hypofunction)
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vi) Other hormonal disorders
vii) Immunosuppressive and anti-inflammatory
medications for the treatment of comorbid
conditions
viii) Cancer
ix) Organic disorders of central nervous system
x) Psychological disorders
After selection, all patients were identified into
two groups.
The first group was composed of patients without
statin therapy neither prior nor after the CABG. We
named this group as nSt-patients.
The second group was composed of patients who
have statin therapy for at least 3 days prior to the CABG
and continuously after the operation. We named this
group as St-patients. Period 3 days was defined randomly
according to the literature data. It is supposed that antiinflammatory effect of statins begins to appear after 3
days of starting the therapy.19 In our study only original
atorvastatin and rosuvastatin were used. We made no
reckoning of the dose of statins.

postoperative periods. The source of patient's data is a
hospital chart.

Outcomes
AF event after CABG was endpoint of presented
study.
A postoperative AF event was defined an AF
episode lasting for more than 5 minutes occurred
postoperatively in the period 7 days after CABG. In
accordance with the study protocol and clinically
appropriate, all patients were under 24-hour bedside
electrocardiography and blood pressure (BP) monitoring
for the first 96 hours after the surgery. AF episode was
confirmed on the evidence of the above data.

Patients
In 2013, 415 CABGs were performed in
Department of Surgical Treatment for Interactive
Pathology, Bakoulev Scientific Center for
Cardiovascular Surgery (Moscow, Russia). Our
retrospective study included medical records on 225
patients with coronary heart disease (CHD) (196 men
and 29 women), aged 57.5±7.9 years (mean±SD), who
underwent CABG in in 2013. Two hundred and sixteen
patients were excluded from the study because of
nonfulfilment of the enrollment criterions. Workflow
of patients' selection is presented in Figure 1.
Healthy status of all included patients was
confirmed by the results of clinical investigation.
Finally, we have identified 93 (41%) nSt-patients
and 132 (59%) St-patients.

Data Collection
Clinical data (results with data physical
examinations, instrumental and laboratory
investigations) on all included patients were obtained
during their hospital treatment in pre-, intra- and
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Figure 1. Patients' selection in this study.
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Statistical Analysis
We apply the Shapiro-Wilk test to check whether
the data were approximately normally distributed.
Continuous variables were reported as medians (Me)
with inter-quartile ranges (Q1, Q3) for non-normal data
or mean (M) with standard deviation (SD) for normal
data. Categorical data were presented as frequencies and
percentages. To compare the variables between the
patients' groups we used the Mann-Whitney test. The
difference between the two proportions was assessed
by t-test. Pared values were evaluated using Spearman's
correlation (R). The risk of occurrence of postoperative
AF was evaluated using the Cox-regression model. The
obtained estimations were considered statistically
significant if P<0.05.
We used the software package Statistica 10.0
(StatSoft Inc., Tulsa, Oklahoma, USA) for statistical
analysis.

AF postoperatively. The analysis showed that peak
WBC concentrations occurred on the day of onset of
arrhythmia (Figure 3). In this subgroup, WBC count was
10.4 (7.5, 12.3) ×109 e/L on Day 1 after surgery and
12.3 (10.0, 14.0) ×109 e/L on the day of onset of AF
(P=0.008). The difference remained significant.
The risk of occurrence of postoperative AF was
evaluated using the Cox regression model (Table 2). The
indicators with high correlation we not included together
in the analysis. Such factors as «Prior AF» and
«Antiarrhythmic therapy», «Prior MI» and «Therapy
with beta-blockers» and «Therapy with ACE-Is» had
high correlation (R<0.7). So only «Prior AF», «Prior
MI» were included in the analysis.
Of these clinical variables included in Cox
regression model, only prior AF and statin medication
use were found to be statistically meaningful for the
risk of AF after CABG. Results of the evaluation of the
risk of AF in this study are given in Table 3.

Results

Discussion

The studied groups of St-patients and nSt-patients
were comparable most anthropometric, clinical,
instrumental and laboratory characteristics in pre-, intraand postoperative periods. The relevant data for both
groups are presented in Table 1. Significant differences
between groups were found in the rate of AF and blood
leucocytes in the early postoperative period. AF
occurred in 29% of nSt-patients vs 9% in St-patients
(P<0.001).
There was no significant difference in the length
of hospital stay between groups: 9 (7, 11) in nSt-patients
vs 9 (7, 11) in St-patients (P=0.351).
Also, there was a difference between groups in
laboratory values: on Day 4 after surgery, white blood
cells (WBC) count was 10.9 (9.0, 13.0) ×109 e/L in nStpatients and 9.1 (7.6, 10.0) ×109 e/L in St-patients
(P<0.001). On Day 1, WBC count was also lower in Stpatients but the difference was insignificant (P=0.391)
(Figure 2).
AF paroxysms occurred earlier in nSt-patients
than in St-patients: Day 2 (2, 3) vs. Day 3 (3, 5),
P=0.039.
An analysis of WBC count day-to-day changes
was performed in a subgroup of patients who developed
4

Blood WBC as inflammatory markers were
chosen for our study as showing high prognostic value
for the onset of AF.25-27 Some previous studies have
shown neutrophils level more specific as an independent
predictor of postoperative AF.26 It is known that during
cardioplegia and bypassdue to ischemia and reperfusion,
neutrophils are involved and secrete a wide variety of
inflammatory biomarkers.
This study shows a strong correlation between
blood WBC count and the risk of postoperative AF: the
rate of AF was significantly higher in patients with a
higher WBC count. Furthermore, peak WBC
concentrations were observed on the day of onset of
AF.
Statin medication prior to CABG and in the
postoperative period was associated with reductions in
the rate of postoperative AF and blood WBC count. In
St-patients, peak blood WBC count occurred later than
in nSt-patients. In our study, the delay was 1 day. The
anti-inflammatory effect of statins seems to be due to
their pleiotropic properties. A considerable reduction of
the activity of all inflammatory markers under exposure
to 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA)
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Table 1. Anthropometric and clinical characteristics of studied patients
Parameter
Age, years, M±SD
Male sex, no. (%)
Body weight, kg, M±SD
BMI, kg/m2, M±SD
Smokers, no. (%)
Hypertension, no. (%)
Prior MI, no. (%)
Diabetes, no. (%)
Prior CVA, no. (%)
CRF, no. (%)
Prior AF, no. (%)
Euro SCORE II, Me (Q1, Q3)
Prior antiarrhythmic therapy, no. (%)
Prior PCI, no. (%)
Prior therapy with ACE-Is, no. (%)
Prior therapy with beta-blockers, no. (%)
LAD, cm, Me (Q1, Q3)
EDD, cm, Me (Q1, Q3)
EDV, mL, Me (Q1, Q3)
EFLV, %, Me (Q1, Q3)
Preoperative potassium, mmol/L, Me (Q1, Q3)
Preoperative WBC, x109/mL, Me (Q1, Q3)
Preoperative creatinine, mmol/L, Me (Q1, Q3)
Off-pump CABG, no. (%)
On-pump CABG, no. (%)
CPB time, min, Me (Q1, Q3)
Aortic cross-clamping time, min, Me (Q1, Q3)
APV time, h, Me (Q1, Q3)
Number of grafts, Me (Q1, Q3)
RCA bypass, no. (%)
Graft thrombosis, no. (%)
Cessation of cardiotonic support, days, Me (Q1, Q3)
Postoperative AF, no. (%)
Day of AF onset, Me (Q1, Q3)
WBC count on Day 1, x109/mL, Me (Q1, Q3)
WBC count on Day 4, x109/mL, Me (Q1, Q3)
WBC count on the day of AF onset, x109/mL, Me (Q1, Q3)
Postoperative pneumonia, no. (%)
Number of bed-days, Me (Q1, Q3)
Intensive unit bed-days, Me (Q1, Q3)
Antiarrhythmic therapy, no. (%)
Therapy with ACE-Is, no. (%)
Therapy with beta-blockers, no. (%)

nSt-patients (n=93)

St-patients (n=132)

P-level

58.1±8.2
81 (87.1)
83.0±12.8
28,2±4.8
30 (32.3)
72 (77.4)
58 (62.4)
9 (9.7)
1 (1.1)
28 (30.1)
8 (8.6)
1.87 (0.94, 2.15)
8 (8.6)
3 (3.2)
91 (97.8)
92 (98.9)
4.1 (3.9, 4.5)
5.4 (5.0, 5.7)
135 (124, 159)
60 (54, 63)
4,1 (3.7,4.3)
9.9 (6.9, 10.1)
93 (83, 103)
74 (79.6)
18 (20.4)
99 (45, 123)
56 (45, 66)
7 (4, 9)
2 (2, 3)
51 (54.8)
3 (3.2)
3 (2, 3)
27 (29.0)
2 (2, 3), n=27
10.4 (7.5, 12.3)
10.9 (9.0, 13.0)
12.3 (10.0, 14.1), n=27
3 (3.2)
9 (7, 11)
1 (1, 2)
8 (8.6)
93 (100)
92 (98.9)

57.1±7.6
114 (86.4)
83.1±11.1
28,3±4.1
53 (40.2)
94 (71.2)
74 (56.1)
11 (8.3)
3 (2.3)
37 (28.0)
8 (6.1)
1.87 (0.94, 2.15)
8 (6.1)
7 (5.3)
129 (97.7)
129 (97.7)
4.1 (3.9, 4.4)
5.3 (4.9; 5.5)
134 (115, 154)
60 (56, 64)
4,15 (3.8,4.3)
9.6 (7.3, 11.8)
93 (86.5, 102.5)
116 (87.9)
18 (12.1)
96 (65, 127)
57 (45, 66)
7 (4, 8)
2 (2, 3)
77 (58.3)
1 (0.8)
3 (2, 3)
12 (9.1)
3 (3, 5), n=12
9.5 (7.4, 12.0)
9.1 (7.6, 10.0)
14.0 (10.0, 14.0), n =12
7 (5.3)
9 (7, 11)
1 (1, 3)
8 (6.1)
132 (100)
130 (98.5)

0.491
0.872
0.744
0.723
0.221
0.299
0.166
0.537
0.504
0.735
0.126
0.754
0.201
0.453
0.951
0.773
0.791
0.111
0.202
0.411
0.841
0.412
0.958
0.063
0.631
0.342
0.715
0.854
0.746
0.603
0.161
0.055
<0.001
0.039
0.391
<0.001
0.960
0.452
0.351
0.910
0.201
1
0.943

BMI, body mass index; CVA, cerebral vascular accident; MI, myocardial infarction; CRF, chronic renal failure; ACE-Is, angiotensinconverting-enzyme inhibitors; LAD, left atrial diameter; EDD, end-diastolic dimension of left ventricle; EDV, end-diastolic volume of
left ventricle; EFLV, ejection fraction of left ventricle; CPB, cardiopulmonary bypass; APV, artificial lung ventilation; RCA, right
coronary artery; WBC, white blood cells.
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Figure 2. Blood WBC count in studied groups on Day 1 after
surgery and Day 4 after surgery.

Figure 3. Blood WBC count on Day 1 after surgery, and on
the day of onset of AF.

Table 2. Clinical variables used in the Cox model of regression for evaluation of the risk of occurrence of AF
χ2=38.42, P<0.001)
in patients after CABG (χ
Parameter
Statins
Prior AF
Number of grafts
Diabetes
EDD
Preoperative creatinine
Age
CRF
Prior MI
EF
Prior PCI
CPB time
Sex
etc.

Regression
coefficient β

Standard error

Risk index
Exp (B)

Wald test

P

-1.145
1.251
0.419
-1.088
0.453
-0.017
0.023
0.505
0.359
0.014
-0.462
-0.001
0.012

0.357
0.396
0.231
0.779
0.356
0.014
0.022
0.505
0.380
0.021
1.037
0.003
0.520

0.318
3.493
1.520
0.336
1.572
0.982
1.023
1.657
1.432
1.014
0.629
0.999
1.012

10.24
9.96
3.28
1.94
1.61
1.38
1.02
0.99
0.89
0.43
0.19
0.14
<0.01

0.001
0.002
0.070
0.163
0.204
0.238
0.310
0.317
0.344
0.510
0.655
0.706
0.981

Note. Statistically significant predictors (P<0.005) of postoperative AF and first 11 non-significant factors are summarized in
Table 2 (presented in descending order of significance). Other indicators included in the multiple analysis (Table 1) are not
presented in the Table 2.
6
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χ2=16.14, P<0.001)
Table 3. Evaluation of the risk of AF depending on statin medication and prior AF variables (χ
Risk factors
Statins
Prior AF
Yes
No
Yes
No

No
No
Yes
Yes

Risk of AF in accordance
with the Cox model of regression

Level of
AF risk

Rate of AF in
this study

0.31
1.00
1.15
3.68

Low
Moderate
High
Very high

6.5%
25.6%
50.0%
54.5%

reductase inhibitors seems to be due to their effect on
neutrophils: increasing apoptosis and enhancing cytokine
secretion. Chello et al. in their blind placebo-controlled
study showed that using simvastatin 40 mg/daily during
7 days after surgery reduced peak anti-inflammatory
markers count (interleukin 6 an 8). 28 The antiinflammatory effect of statins begins to appear before
their hypolipidemic effect. In our study, statin
medication started just in 3 days before the intervention
led to significant results in terms of prevention of
postoperative AF.
In our study, the regression analysis showed that
only two factors could have significant influence on the
onset of postoperative AF, which are prior AF and statin
medication. Moreover prior AF increases the risk of
postoperative AF significantly due to arrhythmogenic
cardiomyopathy while the statin medication significantly
decreased the risk of postoperative AF (P=0.001). In
accordance with the Cox model of regression, the risk
of AF was lowest (6.5%) in St-patients without a history
of AF, moderate (25.6%) in nSt-patients without a
history of AF, high (50%) in St-patients with prior AF
and very high (54.5%) in nSt-patients with a prior AF.
Marìn et al. obtained similar results in a study on
234 patients.29 In the multivariant analysis, statin therapy
was found to be associated with a reduction of the rate
of AF after GABG (HR 0.52, 95% CI 0.28; 0.96,
P=0.038). The TIMP-1/MMP-1 ratio (TIMP-1 is tissue
inhibitor matrix metalloproteinase-1, MMP-1 is matrix
metalloproteinase-1) in 24 h after GABG was higher in
patients without a history of AF (P=0.043). Statin
medication was associated with increases of both the
TIMP-1 level and TIMP-1 / MMP-1 ratio (P=0.027 and
P=0.036, respectively). It should be noted that, unlike
us, Marìn used TIMP-1 and MMP-1 as inflammatory
markers.
J HK Coll Cardiol, Vol 24

Kimura et al. showed experimentally that
fluvastatin could inhibit the activities of leukotriene B4
and platelet activation factor.30 The lipid-independent
anti-inflammatory effect was confirmed in an
experimental study performed by Scalia et al.31 who
observed an inhibiting effect of simvastatin and
cerivastatin on actin-mediated membrane polymerization
and integrin-binding molecules of CD 11a, CD 18 and
VLA-4.
As far back as 1999, Ikeda et al. found that
fluvastatin and simvastatin exert a considerable
inhibiting effect on angiotensin 2-induced secretion of
interleukin-6 in the culture of human SMCs. This effect
was accompanied by a reduction in the level of Creactive protein.32
In a few studies, it was shown that statin therapy
could lead to the decrease in the length of hospital stay
due to a reduction of the AF.5-7 We have not seen this in
our study.
No significant association between several
clinical characteristics (chronic renal failure, prior
myocardial infarction, etc.) and risk of AF after CABG
was shown. It was also shown in previous studies.33-35
Whereas there is different data on the influence of
chronic renal failure on the onset of postoperative AF
showing as significant association36,37 as well as no
association.38,39
Otherwise other studies have shown significant
association between postoperative AF after CABG and
left atrial parameters,40 perioperative intra-aortic balloon
pump use,41 which was not shown in our study. The
reason may be due to the design of our study, which is
reflected in the Limitations section.
Postoperative pneumonia according to some
authors was also associated with postoperative AF.42 In
our study it was a rare complication. Moreover the
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statistical analysis was presented for pre- and
intraoperatively characteristics, so the influence of postoperative pneumonia could not be evaluated according
to the design of the study.

Conclusion
AF is one of potential complications that can
cause hemodynamic instability in patients after GABG
and increase the risk of stroke and postoperative
mortality. In our study, we showed an association
between the use of statin medication and AF in early
postoperative period. Anti-inflammatory properties
demonstrated by statins are one of the factors that may
explain why their beneficial effects on the clinical course
and prognosis of the atherosclerotic vascular disease are
more pronounced than could be expected.

Limitations
There are some limitations of our study. The main
one is related to the design. As it was retrospective trial,
there was no randomization and placebo-control.
It is known that all the patients with coronary
artery disease should get statin medication according to
the updated ESC/ACC/AHA guidelines. And if conduct
prospective randomized trial half of the patients are
supposed to discontinue the lipid-lowering therapy. In
our opinion it is impossible from the ethical position
according to the modern recommendations. In a
retrospective design of the study we were able to enroll
the patients who were not taking statins for other reasons
(social factors, economic factors, etc.).
It should be noticed that the authors did not
analyze the reasons for not receiving statin therapy prior
to the surgery. The study was retrospective and to
perform CABG there is no need for patients to receive
statin therapy. Statin medication and lipid levels control
is usually within the outpatient cardiologists cognizance.
In addition, it is known, that outpatient treatment
compliance is still unsolved problem.
In the presented study we have not evaluated the
influence of different doses and duration of statin therapy

8

due to lack of retrospective information. Chen et al.43
evaluated the correlation between statin therapy
effectiveness in postoperative AF prevention and
different doses and duration of the therapy. Analysis has
shown statistically significant association between the
duration of preoperative statin therapy and risk of
postoperative AF, but no significant association was
show between statin doses and lower risk of
postoperative AF.
The main limitation of the study was no
information about serum lipid profile before the
operation, so the information was not included into the
analysis. So we have no statistically significant data to
propose that the anti-fibrillatory effect of statin extend
beyond its lipid lowering action.
Such factors as «Prior AF» and «Antiarrhythmic
therapy», «Prior MI» and «Therapy with beta-blockers»
and «Therapy with ACE-Is» had high correlation
between each other (R<0.7) and so were excluded from
the analysis.
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